Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while YieldMax NVDA Option Income Strategy ETF trades at $12.58 (market cap $1.45B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9.8× YieldMax NVDA Option Income Strategy ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| CRL | NVDY | |
|---|---|---|
Market Cap | $14.23B | $1.45B |
Volume | 1,176,885 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $310.77 | $17.21 |
52-Week Low | $149.93 | $11.58 |
Typical Hold Time | 33 Days | 43 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
NVDY trades at $12.565, down 3.42% today amid bearish technical signals. The ETF shows consistent weekly dividend distributions but faces structural limitations on upside participation. Recent analyst coverage highlights declining volatility in underlying NVDA shares, reducing option income potential while NAV erosion remains a concern.
Outlook remains cautious as the fund's high distribution yield comes at the cost of long-term capital appreciation. Key risks include capped upside participation and dependency on NVDA volatility. Investors seeking pure NVDA exposure may find direct ownership more attractive for growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
